A new artificial intelligence (AI) model utilizing electrocardiogram (ECG) data demonstrates​ improved accuracy in ⁤predicting​ severe liver disease and risk of death among patients awaiting liver transplantation. Developed‌ by researchers, the AI-cirrhosis-ECG model – known as ACE – ‌addresses limitations in the current standard, the Model for End-Stage⁣ Liver Disease (MELD) score.

Beyond the MELD Score

The MELD score, ‍while widely used, doesn’t fully account for critical complications of liver disease like ascites ‌(fluid buildup) and portal hypertension (high blood pressure in the ​liver).ACE overcomes this by identifying disease indicators that​ MELD⁤ misses, leading​ to ⁣more⁣ precise risk stratification. Findings were published in Jhep Reports in 2024.

How ACE Works

The ACE model was trained on data ‍from over 75,000 patients.Analysis revealed a clear pattern: risk ⁣scores progressively increased as patients approached transplant ⁣and then decreased⁤ following the surgery. ⁣This dynamic tracking provides a more nuanced understanding of a patient’s condition over time.

Optimizing Organ Allocation and Patient Care

Experts believe ACE has the potential to substantially improve the liver transplantation process. Bashar Aqel,MD,director⁢ of the Mayo Clinic Transplant Center in Phoenix,suggests the model ⁤could be ‍integrated with MELD to optimize how organs are allocated ‍to those most in need. Andrew Keaveny, MD, a transplant hepatologist ‌at Mayo Clinic in ​Jacksonville, Florida, anticipates that ACE will refine decisions regarding transplant listing and ultimately lead ⁢to better patient outcomes.

Service‌ Value: More accurate risk assessment means patients receive the care they need, when⁢ they need it. Improved ‌organ allocation ensures that life-saving transplants reach those with the highest priority, maximizing the impact of a limited resource.